
Jakko A Nieuwenhuijzen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6691421/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. European Urology, 2021, 79, 480-488.	0.9	198
2	Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non–muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients. European Urology, 2018, 73, 226-232.	0.9	95
3	Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non–muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non–muscle-invasive Bladder Cancer Guidelines Panel Study. European Urology Oncology, 2021, 4, 182-191.	2.6	54
4	Detection of Recurrent Prostate Cancer Using Prostate-specific Membrane Antigen Positron Emission Tomography in Patients not Meeting the Phoenix Criteria for Biochemical Recurrence After Curative Radiotherapy. European Urology Oncology, 2021, 4, 821-825.	2.6	42
5	Posterior, Anterior, and Periurethral Surgical Reconstruction of Urinary Continence Mechanisms in Robot-assisted Radical Prostatectomy: A Description and Video Compilation of Commonly Performed Surgical Techniques. European Urology, 2019, 76, 814-822.	0.9	41
6	Prostate Sparing Cystectomy for Bladder Cancer: 20-Year Single Center Experience. Journal of Urology, 2014, 191, 1250-1255.	0.2	35
7	Automated Detection and Grading of Non–Muscle-Invasive Urothelial Cell Carcinoma of the Bladder. American Journal of Pathology, 2020, 190, 1483-1490.	1.9	34
8	Comparative Analysis of Urine Fractions for Optimal Bladder Cancer Detection Using DNA Methylation Markers. Cancers, 2020, 12, 859.	1.7	31
9	Sexual Dysfunction and Bother Due to Erectile Dysfunction in the Healthy Elderly Male Population: Prevalence from a Systematic Review. European Urology Focus, 2020, 6, 776-790.	1.6	29
10	Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 440-448.	0.8	27
11	The diagnostic accuracy of methylation markers in urine for the detection of bladder cancer: a systematic review. Epigenomics, 2018, 10, 673-687.	1.0	24
12	A two-gene methylation signature for the diagnosis of bladder cancer in urine. Epigenomics, 2019, 11, 337-347.	1.0	23
13	Genital Gender-Affirming Surgery Without Urethral Lengthening in Transgender Men—A Clinical Follow-Up Study on the Surgical and Urological Outcomes and Patient Satisfaction. Journal of Sexual Medicine, 2020, 17, 2478-2487.	0.3	22
14	Development of a patient decision aid for the treatment of localised prostate cancer: a participatory design approach. Journal of Clinical Nursing, 2016, 25, 1131-1144.	1.4	21
15	Reproducibility and Prognostic Performance of the 1973 and 2004 World Health Organization Classifications for Grade in Non–muscle-invasive Bladder Cancer: A Multicenter Study in 328 Bladder Tumors. Clinical Genitourinary Cancer, 2018, 16, e985-e992.	0.9	19
16	Needle-based optical coherence tomography for the detection of prostate cancer: a visual and quantitative analysis in 20 patients. Journal of Biomedical Optics, 2018, 23, 1.	1.4	17
17	Bladder cancer detection in urine using DNA methylation markers: a technical and prospective preclinical validation. Clinical Epigenetics, 2022, 14, 19.	1.8	16
18	A systematic review on mutation markers for bladder cancer diagnosis in urine. BJU International, 2021, 127, 12-27.	1.3	14

#	Article	IF	CITATIONS
19	An immediate, single intravesical instillation of mitomycin C is of benefit in patients with non–muscle-invasive bladder cancer irrespective of prognostic risk groups. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 400.e7-400.e14.	0.8	13
20	Long-term survival and complications following bladder-preserving brachytherapy in patients with cT1-T2 bladder cancer. Radiotherapy and Oncology, 2019, 141, 130-136.	0.3	11
21	Biochemical Persistence of Prostate-specific Antigen after Robot-assisted Laparoscopic Radical Prostatectomy: Tumor localizations using PSMA PET/CT imaging. Journal of Nuclear Medicine, 2021, 62, jnumed.120.252528.	2.8	11
22	The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer. Journal of Urology, 2021, 205, 1655-1662.	0.2	10
23	The Origin of Tumor DNA in Urine of Urogenital Cancer Patients: Local Shedding and Transrenal Excretion. Cancers, 2021, 13, 535.	1.7	9
24	The effect of timing of an immediate instillation of mitomycin C after transurethral resection in 941 patients with nonâ€muscleâ€invasive bladder cancer. BJU International, 2018, 122, 571-575.	1.3	8
25	Management impact of 18F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2960-2969.	3.3	8
26	Robot-assisted Laparoscopic Implantation of Brachytherapy Catheters in Bladder Cancer. European Urology, 2018, 74, 369-375.	0.9	7
27	Confocal Laser Endomicroscopy and Optical Coherence Tomography for the Diagnosis of Prostate Cancer: A Needle-Based, In Vivo Feasibility Study Protocol (IDEAL Phase 2A). JMIR Research Protocols, 2018, 7, e132.	0.5	7
28	The ultimate radiochemical nightmare: upon radio-iodination of Botulinum neurotoxin A, the introduced iodine atom itself seems to be fatal for the bioactivity of this macromolecule. EJNMMI Research, 2015, 5, 5.	1.1	6
29	Effectiveness, cost-utility and implementation of a decision aid for patients with localised prostate cancer and their partners: study protocol of a stepped-wedge cluster randomised controlled trial. BMJ Open, 2017, 7, e015154.	0.8	6
30	Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer. PLoS ONE, 2020, 15, e0239414.	1.1	6
31	When Limb Surgery Has Become the Only Life-Saving Therapy in FOP: A Case Report and Systematic Review of the Literature. Frontiers in Endocrinology, 2020, 11, 570.	1.5	5
32	Radiotherapy in Fibrodysplasia Ossificans Progressiva: A Case Report and Systematic Review of the Literature. Frontiers in Endocrinology, 2020, 11, 6.	1.5	5
33	Objectifying grade in Ta-T1 urothelial carcinomas of the bladder using proliferative and quantitative markers: A multicentre study in 310 bladder tumors. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 530.e1-530.e8.	0.8	4
34	Effectiveness of Preoperative Depilation of the Urethral Donor Site for Phalloplasty: Neourethral Hair Growth and its Effects on Voiding. European Urology Focus, 2020, 6, 770-775.	1.6	4
35	Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer. Journal of Urology, 2021, 205, 1100-1109.	0.2	4
36	T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non–muscle-invasive Bladder Cancer Spectrum. European Urology Focus, 2022, , .	1.6	4

#	Article	IF	CITATIONS
37	Value of a Marker Lesion in Non-Muscle-Invasive Bladder Cancer Patients Treated with Interleukin-2 Instillations: A Randomized Controlled Multicentre Trial. Urologia Internationalis, 2019, 102, 69-76.	0.6	3
38	Minimally invasive perineal redo surgery for rectovesical and rectovaginal fistulae: A case series. International Journal of Surgery Case Reports, 2020, 77, 733-738.	0.2	2
39	Bladder necrosis: â€~A man without a bladder'. BMJ Case Reports, 2018, 2018, bcr-2016-217769.	0.2	2
40	An immediate, single instillation of mitomycin C in non-muscle invasive bladder cancer: can we define which patients do and do not benefit?. Translational Andrology and Urology, 2019, 8, S346-S347.	0.6	1
41	Intraoperative Strategies to Reduce Catheter-Related Bladder Discomfort in the Early Postoperative Period after Robot-Assisted Radical Prostatectomy. Journal of Urology, 2021, 205, 1671-1680.	0.2	1
42	Trial-based Cost-effectiveness Analysis of an Immediate Postoperative Mitomycin C Instillation in Patients with Non–muscle-invasive Bladder Cancer. European Urology Open Science, 2022, 37, 7-13.	0.2	1
43	Case Presentation: Botox Versus Nerve Stimulation. European Urology Focus, 2017, 3, 529-530.	1.6	0
44	Authors' response to Letter to the Editor "Don't forget Arnhem― Radiotherapy and Oncology, 2020, 147, 237.	0.3	0
45	Reply by Authors. Journal of Urology, 2021, 205, 1108-1109.	0.2	0
46	Reply by Authors. Journal of Urology, 2021, 205, 1662-1662.	0.2	0
47	Reply by Authors. Journal of Urology, 2021, 205, 1680-1680.	0.2	0